Simultaneous broad protection against Ebola Sudan, Marburg and Lassa viruses conferred by a DNA primed MVA-vectored multivalent vaccine

Abstract Sub-Saharan Africa continues to experience recurrent outbreaks of zoonotic viral diseases that spill over unpredictably from animal reservoirs into human populations. In many regions, mpox co-circulates with viral hemorrhagic fevers (VHFs) caused by Ebola Sudan virus (SUDV), Marburg virus (MARV), and Lassa fever virus (LASV). Overlapping clinical syndromes that these VHF cause challenge surveillance, diagnostics and timely deployment of effective countermeasures. A single vaccine capable of protecting against these biologically and genetically distinct pathogens would markedly reduce the cost and complexity of outbreak response, lessen dependence on emergency international aid, and strengthen long-term health system resilience. Here, we report on the development of an MVA-based mpox vaccine engineered to express computationally designed, broad-coverage antigens targeting SUDV, MARV and LASV. In preclinical challenge studies, this multivalent vaccine elicited robust immune responses and conferred significant protection against lethal infection from all three pathogens in parallel challenge experiments. These findings establish preclinical proof-of-concept for a single, broadly protective VHF vaccine and support its clinical development for deployment across diverse settings in Sub-Saharan Africa. Significance Outbreak control in Sub-Saharan Africa is challenged by the co-circulation of different high consequence human infections such as mpox and diverse viral hemorrhagic fevers (VHF) such as SUDV, MARV, and LASV pathogens. These VHFs have overlapping early clinical syndromes, complicating triage and delaying effective targeted interventions. We developed a single MVA-based vaccine encoding computationally designed, conserved antigens from all three VHFs encoded within the MVA vector analogous to the licensed mpox vaccine. In simultaneous challenge models, this multivalent vaccine elicited robust humoral and cellular responses and conferred significant protection against lethal infection by each hemorrhagic fever pathogen. This work provides preclinical proof-of-concept for a unified, broadly protective countermeasure compatible with existing MVA-mpox vaccine manufacturing and deployment experience. By reducing dependence on rapid differential diagnostics and streamlining logistics relative to maintaining multiple pathogen-specific vaccine stockpiles, this approach can lower costs, accelerate response, and increase equity of access during syndromic outbreaks. The platform’s engineered antigen breadth and human safety profile of MVA together support a pragmatic translational pathway toward clinical evaluation and regional readiness for zoonotic spillover events that are intensifying with human and environmental changes. Competing Interest Statement SoFed, S.B.S., S.A., S.P., R.K., R.W., and J.L.H. are employees or shareholders of DIOSynVax Ltd. S.F. is an employee of Microsoft.